KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Tumor-Derived Exosomes Mediate Platinum Resistance in Ovarian Cancer Through Regulation of EMT

    Thumbnail
    View/Open
    Crow_ku_0099D_14781_DATA_1.pdf (5.445Mb)
    Issue Date
    2016-08-31
    Author
    Crow, Jennifer M.
    Publisher
    University of Kansas
    Format
    177 pages
    Type
    Dissertation
    Degree Level
    Ph.D.
    Discipline
    Pathology & Laboratory Medicine
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Nano-sized vesicles, termed exosomes, have been implicated in the transfer of oncogenic proteins and genetic material from one cell to another. We speculated this may be one mechanism by which an intrinsically platinum-resistant population of epithelial ovarian cancer (EOC) cells imparts its influence on surrounding tumor cells. To explore this possibility we have utilized the platinum-sensitive A2780 cell line and independent platinum-resistant derivatives, e.g., CP70 and C30, as well as a non-related platinum-resistant cell line, OVCAR10. We find A2780 cells treated with exosomes derived from highly resistant cells demonstrate up to a ~2-fold increase (p<0.05) in resistance to carboplatin as compared to treatment with isolated autologous exosomes. Importantly, this exosome-associated phenotype is stable and associated with increased epithelial to mesenchymal transition (EMT) characteristics. In addition, we identified previously unreported somatic mutations in the Mothers Against Decapentaplegic Homolog 4 (SMAD4), only in cells (OVCAR10, C30, and CP70) that demonstrated robust acquired resistance after platinum therapy. Cells displaying mutations in SMAD4 exhibited significant changes in EMT-related markers following treatment with carboplatin. Interestingly, exosomes derived from A2780 cells engineered to exogenously express specific SMAD4 mutations resulted in ~1.7-fold (p<0.05) increase in resistance as compared to exosomes isolated from exogenous wildtype SMAD4 (SMAD4WT) expressing A2780 cells, suggesting these mutations are contributing to the development of a resistant phenotype. Additionally, cells expressing mutations in SMAD4 exhibit a loss of phosphorylation of SMAD2 but retain activated SMAD3, which is important for EMT. Importantly, inhibition of SMAD3 via the small molecule inhibitor, SIS3, reversed the EMT phenotype and acted synergistically with carboplatin to enhance cell death. Lastly, we identified a clinically relevant inhibitor of SMAD3, Eribulin Mesylate (Halaven®), which also acted synergistically with carboplatin in vitro. Altogether, our findings provide the first evidence that ovarian tumor cells use exosomes as a vehicle to achieve tumor cell-cell crosstalk and this exchange advantageously impacts the recipient cells response to platinum. We continue to describe a novel mechanism of action by which an EMT phenotype is perpetuated via exchange of tumor-derived exosomes, ultimately leading to the development of a subpopulation of chemotherapy refractory cells. Importantly, we present a novel therapeutic strategy that targets resistant cells and ‘tricks’ them into responding once again to the most effective therapeutics to date, cisplatin and carboplatin.
    URI
    http://hdl.handle.net/1808/25365
    Collections
    • Dissertations [3958]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    LoginRegister

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps